Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABLe
2024-512276-35-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of selinexor in multiple myeloma (MM), sponsored by University Hospital Odense. Primary endpoint: Overall response rate at end of induction. Planned start Aug 2021; status: authorised.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-512276-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512276-35-00.